APORPHINOID MATRIX METALLOPROTEINASE INHIBITORS

摘要

Use of a compound of formula (I) wherein R1 represents hydrogen, hydroxy, acyl, halogenyl or C1-C6-alkyl; R2 represents hydrogen, hydroxy, halogenyl, cyano, C1-C6-alkyl, or acyl; R3 and R4 represent independently of each other hydrogen, hydroxy, halogenyl, C1-C7-alkyl, acyl or a monocycle; R5, and R6 represent independently of each other hydrogen, hydroxy, mercapto, C1-C8-alkyl, C1-C7-alkoxy or acyl; R7 represents hydrogen, hydroxy, halogenyl or amino; R8 represents hydrogen, hydroxy, mercapto, C1-C8-alkyl, acyl or R8 and R9 represent together O-(CH2)n-O with n equals 1 or 2; R9 represents hydroxy, mercapto, C1-C7-alkoxy or C1-C7-alkylthio; R10 represents hydrogen, hydroxy, mercapto, halogenyl or amino, C1-C16-alkyl, acyl, an optionally substituted mono- or bicyclus; and pharmacologically acceptable salts or prodrugs thereof, to produce pharmaceutical agents for the treatment of diseases where MMP activity is involved, processes for their production and pharmaceutical agents which contain these compounds having a matrix metalloprotease-inhibitory action.